Cargando…
Frontiers in Drug Research and Development for Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is idiopathic, lifelong, immune-mediated diseases, for which curative therapies are not yet available. In the last 15 years, the introduction of monoclonal antibodies targeting tumor necrosis factor-α, a cytokine playing a key role in bowel inflammation, has revoluti...
Autores principales: | Currò, Diego, Pugliese, Daniela, Armuzzi, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481609/ https://www.ncbi.nlm.nih.gov/pubmed/28690543 http://dx.doi.org/10.3389/fphar.2017.00400 |
Ejemplares similares
-
Update on the management of inflammatory bowel disease: specific role of adalimumab
por: Guidi, Luisa, et al.
Publicado: (2011) -
Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
por: Privitera, Giuseppe, et al.
Publicado: (2021) -
Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease
por: Duan, Linshan, et al.
Publicado: (2021) -
Hotspots and Frontiers in Inflammatory Tumor Microenvironment Research: A Scientometric and Visualization Analysis
por: Zhang, Yuli, et al.
Publicado: (2022) -
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
por: Privitera, Giuseppe, et al.
Publicado: (2021)